Management of atopic dermatitis in routine clinical practice
DOI: 10.32364/2587-6821-2022-6-2-72-78
N.S. Tataurshchikova1, O.I. Letyaeva1,2, A.S. Rusanova1
1Russian University of Peoples’ Friendship, Moscow, Russian Federation
2South Ural State Medical University, Chelyabinsk, Russian Federation
Aim: to assess the efficacy and safety of Admera cream, a cosmetic skin solution for atopic dermatitis (AD).
Patients and Methods: this open-label, prospective, observational study enrolled 32 patients aged 3–27 (mean age 14.6±2.4 years) with mild-to-moderate AD. Patients were followed up in the outpatient settings over 1 month. Disease severity was evaluated based on the SCORAD index. Xerosis severity was assessed using a visual analogue scale (VAS). A ≥25% reduction of SCORAD index was considered a significant effect. Admera cream was applied at least once daily. Patients were examined at baseline (screening), on days 1 (visit 1), 14±1 (visit 2), and 28±2 (visit 3). Treatment satisfaction was self-assessed using the 5-point Likert scale. A score of 5 illustrates high treatment satisfaction.
Results: the mean SCORAD index was 28.4±7.1 at visit 1 and significantly decreased to 18.2±9.2 after 28 days (p<0.001). The mean VAS score was 5.0±1.0 at baseline, 3.5±1.1 after 14 days, and 2.8±1.4 after 28 days (p<0.001). The mean Likert score was 4.5±0.3 in mild AD and 3.7±0.1 in moderate AD. Among 32 participants, 21 patients (65.6%) rated treatment as "excellent,” 10 patients (31.2%) as "good,” and 1 patient (3.1%) as "satisfactory.” No adverse events were reported.
Conclusion: Admera cream is characterized by an excellent safety profile and comfort use. This medication is recommended for long-term treatment of AD.
Keywords: atopic dermatitis, xerosis, filaggrin, filagrinol, emollient, care product.
For citation: Tataurshchikova N.S., Letyaeva O.I., Rusanova A.S. Management of atopic dermatitis in routine clinical practice. Russian Medical Inquiry. 2022;6(2):72–78 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-72-78.
Acknowledgments
The technical edition is supported by JSC "Dr. Reddy’s Laboratories".
About the authors:
Natalya S. Tataurshchikova — Dr. Sc. (Med.), Professor, Head of the Department of Clinical Immunology, Allergy, and Adaptation of the Faculty of Continuous Medical Education of the Medical Institute of the Russian University of Peoples’ Friendship; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0002-3486-8188.
Olga I. Letyaeva — Dr. Sc. (Med.), professor of the Department of Clinical Immunology, Allergy, and Adaptation of the Faculty of Continuous Medical Education of the Medical Institute of the Russian University of Peoples’ Friendship; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; professor of the Department of Dermatovenerology, South Ural State Medical University; 64, Vorovskiy str., Chelyabinsk, 454092, Russian Federation; ORCID iD 0000-0002-9085-6229.
Anna S. Rusanova — specialist on educational and methodical work of the Department of Clinical Immunology, Allergy, and Adaptation of the Faculty of Continuous Medical Education of the Medical Institute of the Russian University of Peoples’ Friendship; 6, Miklukho-Maklaya str., Moscow, 117198, Russian Federation; ORCID iD 0000-0001-6574-1406.
Contact information: Olga I. Letyaeva, e-mail: olga-letyaeva@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 01.02.2022.
Revised 25.02.2022.
Accepted 24.03.2022.
2. Wollenberg A., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. DOI: 10.1111/jdv.14891.
3. Hongwei H., Roan F., Ziegler F. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116–130. DOI: 10.1111/imr.12546.
4. Czarnowicki T., Krueger J.G., Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. DOI: 10.1016/j.jaci.2017.04.004.
5. Čepelak I., Dodig S., Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb). 2019;29(2):020501. DOI: 10.11613/BM.2019.020501.
6. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66 Suppl 1:8–16. DOI: 10.1159/000370220.
7. Perkin M.R., Craven J., Logan K. et al. Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A population-based cross-sectional study. J Allergy Clin Immunol. 2016;138(2):509–516. DOI: 10.1016/j.jaci.2016.03.031.
8. Khan V.V., Tataurschikova N.S., Nurpeissov T.T. The Prevalence of Atopic Dermatitis Among Children and Adults in Kazakhstan. In: Vasenev V., Dovletyarova E., Valentini R. et al., eds. Advanced Technologies for Sustainable Development of Urban Green Infrastructure: Proceedings of Smart and Sustainable Cities 2020. 2021:194–201. DOI: 10.1007/978-3-030-75285-9_18.
9. Ali S., Yosipovitch G. Skin pH: From Basic Science to Basic Skin Care. Acta Derm Venerol. 2013;93(3):26–27. DOI: 10.2340/00015555-1531.
10. Zaslavsky D.V., Barinova A.N. Cutis microbiome in patients with atopic dermatitis, and features of the various basic care products. Medical council. 2018;2:170–176 (in Russ.). DOI: 10.21518/2079-701X-2018-2-170-176.
11. Kalyujzhin O.V. Persistent subclinical inflammation in the skin as a risk factor for relapse in atopic dermatitis: from pathophysiology to treatment. Russian Journal of Allergy. 2017;14(4–5):108–119 (in Russ.). DOI: 10.36691/RJA302.
12. Ellis S.R., Nguyen M., Vaughn A.R. et al. The Skin and Gut Microbiome and Its Role in Common Dermatologic Conditions. Microorganisms. 2019;7(11):550. DOI: 10.3390/microorganisms7110550.
13. Nakagawa S., Matsumoto M., Katayma Y. et al. Staphylococcus aureus Virulent PSMα Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation. Cell Host Microbe. 2017;22(5):667–677. DOI: 10.1016/j.chom.2017.10.008.
14. Baviera G., Leoni M.C., Capra L. et al. Microbiota in healthy skin and in atopic eczema. Biomed Res Int. 2014;2014:436921. DOI: 10.1155/2014/436921.
15. Gonzalez T., Biagini Myers J.M., Herr A.B. et al. Staphylococcal Biofilms in Atopic Dermatitis. Curr Allergy Asthma Rep. 2017;17(12):81. DOI: 10.1007/s11882-017-0750-x.
16. Nodake Y., Matsumoto S., Miura R. et al. Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe. A blinded randomized clinical trial. J Dermatol Sci. 2015;79(2):119–126. DOI: 10.1016/j.jdermsci.2015.05.001.
17. Zaslavskiy D.V., Sobolev A.V., Skrek S.V. et al. Normalization of the epidermal barrier as a method of pathogenetic therapy of atopic dermatitis in children. Vestnik dermatologii i venerologii. 2021;97(5):52–65 (in Russ). DOI: 10.25208/vdv1255.
18. Chromy A. Multispectral 3D Surface Scanning System RoScan and its Application in Inflammation Monitoring and Quantification. Conference Paper. 5th International Conference on Bioimaging. 2018. DOI: 10.5220/0006557601060113.
19. Admera cream leaflet. Cream for the care of dry and sensitive body skin for children 0+ and adults. (Electronic resource.) URL: https://admera.ru/media/docs/instruction.pdf (access date: 22.01.2022) (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
